These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 30234392)
1. The dawn of precision medicine in HIV: state of the art of pharmacotherapy. Mu Y; Kodidela S; Wang Y; Kumar S; Cory TJ Expert Opin Pharmacother; 2018 Oct; 19(14):1581-1595. PubMed ID: 30234392 [TBL] [Abstract][Full Text] [Related]
2. Overview of the pharmacogenetics of HIV therapy. Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nácher I; Soriano V Pharmacogenomics J; 2006; 6(4):234-45. PubMed ID: 16462814 [TBL] [Abstract][Full Text] [Related]
3. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries. De Luca A; Hamers RL; Schapiro JM J Infect Dis; 2013 Jun; 207 Suppl 2():S63-9. PubMed ID: 23687291 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Neely MN; Rakhmanina NY Clin Pharmacokinet; 2011 Mar; 50(3):143-89. PubMed ID: 21294595 [TBL] [Abstract][Full Text] [Related]
5. Precision medicine for HIV: where are we? Cusato J; Allegra S; Nicolò A; Calcagno A; D'Avolio A Pharmacogenomics; 2018 Jan; 19(2):145-165. PubMed ID: 29202676 [TBL] [Abstract][Full Text] [Related]
6. Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects? Masimirembwa C; Dandara C; Leutscher PD OMICS; 2016 Oct; 20(10):575-580. PubMed ID: 27627692 [TBL] [Abstract][Full Text] [Related]
8. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. Andreoni M; Marcotullio S; Puro V; De Carli G; Tambussi G; Nozza S; Gori A; Rusconi S; Santoro MM; Clementi M; Perno CF; d'Arminio Monforte A; Maggiolo F; Castagna A; De Luca A; Galli M; Giacomelli A; Borderi M; Guaraldi G; Calcagno A; Di Perri G; Bonora S; Mussini C; Di Biagio A; Puoti M; Bruno R; Zuccaro V; Antinori A; Cinque P; Croce D; Restelli U; Rizzardini G; Lazzarin A New Microbiol; 2015 Oct; 38(4):443-90. PubMed ID: 26571377 [TBL] [Abstract][Full Text] [Related]
9. An update and review of antiretroviral therapy. Piacenti FJ Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488 [TBL] [Abstract][Full Text] [Related]
10. Development of antiretroviral drug resistance. Wainberg MA; Zaharatos GJ; Brenner BG N Engl J Med; 2011 Aug; 365(7):637-46. PubMed ID: 21848464 [No Abstract] [Full Text] [Related]
11. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond. Murphy RL AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882 [TBL] [Abstract][Full Text] [Related]
12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic Markers: A Path toward Individualized HIV Therapy. García-Blanco D; Gravier-Hernández R; Rabeiro-Martínez CL; Gil Del Valle L; Pérez-Ávila J MEDICC Rev; 2019; 21(2-3):59-68. PubMed ID: 31401638 [TBL] [Abstract][Full Text] [Related]
14. Dolutegravir for the treatment of HIV. Katlama C; Murphy R Expert Opin Investig Drugs; 2012 Apr; 21(4):523-30. PubMed ID: 22380682 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological considerations on the use of antiretrovirals in pregnancy. Colbers A; Greupink R; Burger D Curr Opin Infect Dis; 2013 Dec; 26(6):575-88. PubMed ID: 24152762 [TBL] [Abstract][Full Text] [Related]
16. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China. Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114 [TBL] [Abstract][Full Text] [Related]
17. New antiretroviral agents and the complexity of treatment practices. Smith D J HIV Ther; 2008 Jun; 13(2):25-6. PubMed ID: 18953270 [No Abstract] [Full Text] [Related]
18. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Jiménez-Nácher I; Alvarez E; Morello J; Rodriguez-Nóvoa S; de Andrés S; Soriano V Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):457-77. PubMed ID: 21342079 [TBL] [Abstract][Full Text] [Related]
19. Raltegravir: the first HIV integrase inhibitor. Cocohoba J; Dong BJ Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832 [TBL] [Abstract][Full Text] [Related]